Pioglitazone and barriers to effective post-stroke comorbidity management in stroke survivors with diabetes.

IF 1.2 4区医学 Q4 CLINICAL NEUROLOGY

Neurosciences Pub Date : 2024-01-01 DOI:10.17712/nsj.2024.1.20230043

Hala Azhari, Jonathan Hewitt, Alexander Smith, Martin O'Neill, Terence Quinn, Jesse Dawson

{"title":"Pioglitazone and barriers to effective post-stroke comorbidity management in stroke survivors with diabetes.","authors":"Hala Azhari, Jonathan Hewitt, Alexander Smith, Martin O'Neill, Terence Quinn, Jesse Dawson","doi":"10.17712/nsj.2024.1.20230043","DOIUrl":null,"url":null,"abstract":"Objectives: To explore the barriers preventing pioglitazone use in stroke survivors and primary and secondary stroke care services.Methods: A qualitative grounded theory approached design was used to assess post-stroke diabetes treatments and to assess clinical applicability of pioglitazone as a preventive treatment to minimize its side effects (SEs) associated. Three focus groups were established with 48 participants from Scotland and Wales health board centers during January 2019 to July 2022.Results: A qualitative grounded theory approached design was used to assess post-stroke diabetes treatments and to assess clinical applicability of pioglitazone as a preventive treatment to minimize its SEs associated. Three focus groups were established with 48 participants from Scotland and Wales health board centers during January 2019 to July 2022.Conclusion: These strategies might allow greater treatment adherence by stroke survivors and increased confidence of the health care professionals in their practice. The findings suggest that further research will be needed to facilitate wider usage of pioglitazone in treating people with stroke and health education is necessitate when using diabetes drugs post-stroke.","PeriodicalId":19284,"journal":{"name":"Neurosciences","volume":"29 1","pages":"44-50"},"PeriodicalIF":1.2000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10827012/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurosciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.17712/nsj.2024.1.20230043","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: To explore the barriers preventing pioglitazone use in stroke survivors and primary and secondary stroke care services.

Methods: A qualitative grounded theory approached design was used to assess post-stroke diabetes treatments and to assess clinical applicability of pioglitazone as a preventive treatment to minimize its side effects (SEs) associated. Three focus groups were established with 48 participants from Scotland and Wales health board centers during January 2019 to July 2022.

Results: A qualitative grounded theory approached design was used to assess post-stroke diabetes treatments and to assess clinical applicability of pioglitazone as a preventive treatment to minimize its SEs associated. Three focus groups were established with 48 participants from Scotland and Wales health board centers during January 2019 to July 2022.

Conclusion: These strategies might allow greater treatment adherence by stroke survivors and increased confidence of the health care professionals in their practice. The findings suggest that further research will be needed to facilitate wider usage of pioglitazone in treating people with stroke and health education is necessitate when using diabetes drugs post-stroke.

查看原文本刊更多论文

吡格列酮与中风后糖尿病幸存者有效管理并发症的障碍。

目的方法：采用定性基础理论方法对中风后糖尿病治疗进行评估，并评估吡格列酮作为预防性治疗的临床适用性，以尽量减少其副作用（SEs）：方法：采用定性基础理论方法评估中风后糖尿病治疗，并评估吡格列酮作为预防性治疗的临床适用性，以尽量减少其相关副作用（SE）。2019年1月至2022年7月期间，来自苏格兰和威尔士卫生局中心的48名参与者参加了三个焦点小组：采用定性基础理论方法评估卒中后糖尿病的治疗方法，并评估吡格列酮作为预防性治疗的临床适用性，以尽量减少其相关副作用（SEs）。2019年1月至2022年7月期间，来自苏格兰和威尔士卫生局中心的48名参与者参加了三个焦点小组：这些策略可提高中风幸存者的治疗依从性，并增强医护人员在实践中的信心。研究结果表明，需要进一步开展研究，以促进吡格列酮在中风患者治疗中的广泛应用，并且在中风后使用糖尿病药物时需要开展健康教育。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neurosciences 医学-临床神经学

CiteScore

1.40

自引率

0.00%

发文量

审稿时长

4.5 months

期刊介绍： Neurosciences is an open access, peer-reviewed, quarterly publication. Authors are invited to submit for publication articles reporting original work related to the nervous system, e.g., neurology, neurophysiology, neuroradiology, neurosurgery, neurorehabilitation, neurooncology, neuropsychiatry, and neurogenetics, etc. Basic research withclear clinical implications will also be considered. Review articles of current interest and high standard are welcomed for consideration. Prospective workshould not be backdated. There are also sections for Case Reports, Brief Communication, Correspondence, and medical news items. To promote continuous education, training, and learning, we include Clinical Images and MCQ’s. Highlights of international and regional meetings of interest, and specialized supplements will also be considered. All submissions must conform to the Uniform Requirements.